About Us

SphingoTec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies. Read More...

A UNIQUE WAY OF DISCOVERING DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS


SPHINGOTEC GROUP

 

COMBINING INNOVATIVE BIOMARKER WITH OUTSTANDING TECHNOLOGY

Sphingotec GmbH Logo
NexusDX

 

LATEST NEWS

 

  • The cardiac depressant factor DPP3 is predicting organ failure in burn patients

    The cardiac depressant factor DPP3 is predicting organ failure in burn patients

  • sphingotec expands leadership team and appoints Achim Plum as Managing Director and Chief Commercial Officer

    sphingotec expands leadership team and appoints Achim Plum as Managing Director and Chief Commercial Officer

  • sphingotec’s endothelial function biomarker bio-ADM® improves risk stratification of sepsis patients at ICUs

    sphingotec’s endothelial function biomarker bio-ADM® improves risk stratification of sepsis patients at ICUs

  • Bioactive Adrenomedullin, measured with sphingotec’s bio-ADM® assay plays a key role in septic shock patients as top-line results of AdrenOSS-2 Phase II Study indicate

    Bioactive Adrenomedullin, measured with sphingotec’s bio-ADM® assay plays a key role in septic shock patients as top-line results of AdrenOSS-2 Phase II Study indicate

 

BIOMARKER

 

Sphingotest penKid
sphingotest® penKid®
Sphingotest bio-ADM
sphingotest® bio-ADM®

 
 

A UNIQUE WAY OF DISCOVERING DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS

 

 

 

Top